Shockwave Medical (SWAV) Tops Q3 EPS by 15c

Go back to Shockwave Medical (SWAV) Tops Q3 EPS by 15c

Shockwave Medical Reports Second Quarter 2019 Financial Results

August 5, 2019 4:04 PM EDT

SANTA CLARA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2019.

Recent Highlights

Recognized revenue of $10.0 million for the second quarter of 2019, representing a 339% increase over the second quarter of 2018Appointed industry veterans Keith Dawkins M.D. to Chief Medical Officer and Hajime Tada as General CounselCrossed the 100-patient... More